Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20327891 | 0.90 | MEN1 (0.41) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL13154532 | 0.90 | CES2 (0.42) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL13598099 | 0.90 | MEN1 (0.41) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL15132494 | 0.88 | EPHX2 (0.41) | MEN1KMT2AEPHX2FAAHTSHR | |
| SCHEMBL253658 | 0.88 | CES2 (0.43) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL15259279 | 0.87 | CES2 (0.46) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL13226771 | 0.87 | CES2 (0.46) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL12807256 | 0.87 | CES2 (0.46) | MEN1KMT2AEPHX2FAAHGLP1R | |
| SCHEMBL13640268 | 0.85 | GLP1R (0.48) | EPHX2FAAHGLP1RTSHRRECQL | |
| SCHEMBL13640271 | 0.85 | GLP1R (0.48) | EPHX2FAAHGLP1RTSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-20210324007-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | MEN1 1389/4885KMT2A 4318/4885EPHX2 3687/4885 |
| US-20210324007-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | MEN1 1341/4885KMT2A 4411/4885EPHX2 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.